TLR9 and neoplasm: In situ immunization with vidutolimod (Vidu), a virus-like particle containing a CpG-A TLR9 agonist, has demonstrated antitumor activity in preclinical and early-phase clinical studies; however its effect on tumor-specific CD8+ T cells remain poorly defined.